Cargando…

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy

Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables suc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devos, Gaëtan, Berghen, Charlien, Van Eecke, Henri, Stichele, Arthur Vander, Van Poppel, Hendrik, Goffin, Karolien, Mai, Cindy, De Wever, Liesbeth, Albersen, Maarten, Everaerts, Wouter, De Meerleer, Gert, Joniau, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464259/ https://www.ncbi.nlm.nih.gov/pubmed/32823690 http://dx.doi.org/10.3390/cancers12082271

Ejemplares similares

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial
por: Berghen, Charlien, et al.
Publicado: (2020)

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer
por: Devos, Gaëtan, et al.
Publicado: (2019)

Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
por: Berghen, Charlien, et al.
Publicado: (2020)

Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
por: Ahmadi Bidakhvidi, Niloefar, et al.
Publicado: (2021)

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
por: Rans, Kato, et al.
Publicado: (2022)

Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer
por: Seikkula, Heikki, et al.
Publicado: (2017)

Open and robotic radical prostatectomy
por: van Poppel, Hendrik, et al.
Publicado: (2019)

Preclinical Evidence for the Benefits of Penile Rehabilitation Therapy following Nerve-Sparing Radical Prostatectomy
por: Albersen, M., et al.
Publicado: (2008)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
por: Tosco, Lorenzo, et al.
Publicado: (2018)

A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer
por: De Bleser, Elise, et al.
Publicado: (2020)

Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial
por: Draulans, Cédric, et al.
Publicado: (2018)

Accuracy of dynamic sentinel lymph node biopsy for inguinal lymph node staging in cN0 penile cancer
por: Gebruers, Juanito, et al.
Publicado: (2023)

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
por: Berkovic, Patrick, et al.
Publicado: (2020)

Metastasectomy of oligometastatic urothelial cancer: a single-center experience
por: Muilwijk, Tim, et al.
Publicado: (2020)

Penile metastasis in prostate cancer patients: Two case reports, surgical excision technique, and literature review
por: Landen, Lucas, et al.
Publicado: (2023)

Nine-year survival after iterative metastasectomies for renal cell carcinoma
por: de Oliveira, Tiago Ribeiro, et al.
Publicado: (2019)

Comparison of postoperative complications of ileal conduits versus orthotopic neobladders
por: Demaegd, Liesbeth, et al.
Publicado: (2020)

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial
por: Verghote, Flor, et al.
Publicado: (2021)

Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis
por: Chys, Brecht, et al.
Publicado: (2020)

Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection
por: Moris, Lisa, et al.
Publicado: (2016)

(18)F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study
por: Emonds, Kimy M, et al.
Publicado: (2013)

The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients
por: De Sutter, Thomas, et al.
Publicado: (2016)

Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages ≥cT1b: a single institution, matched analysis
por: Veys, Ralf, et al.
Publicado: (2017)

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
por: Giesen, Alexander, et al.
Publicado: (2023)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
por: Devos, Gaëtan, et al.
Publicado: (2020)

Open Surgery for Localized RCC
por: Vander Eeckt, Kathy, et al.
Publicado: (2007)

Node Oligorecurrence in Prostate Cancer: A Challenge
por: Zapatero, Almudena, et al.
Publicado: (2023)

Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease
por: Macagno, Alban, et al.
Publicado: (2022)

Anatomical mapping of lymph nodes in patients receiving salvage lymphadenectomy based on a positive 11C-choline positron emission tomography/computed tomography scan
por: Deconinck, Steven, et al.
Publicado: (2019)

Lung Radiofrequency Ablation: Potential as a Therapy to Oligometastasis and Oligorecurrence
por: Hiraki, Takao, et al.
Publicado: (2012)

Risk stratification tools in prostate cancer, where do we stand?
por: Clinckaert, Andries, et al.
Publicado: (2021)

(51)Cr-EDTA plasma clearance in children: One, two, or multiple samples?
por: Pottel, Hans, et al.
Publicado: (2022)

Surveillance as an Option for the Treatment of Small Renal Masses
por: Klaver, S., et al.
Publicado: (2008)

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes
por: Wang, Huan-Huan, et al.
Publicado: (2016)

Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?
por: Zilli, Thomas, et al.
Publicado: (2018)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer
por: Mangaj, Akshay, et al.
Publicado: (2021)

Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease
por: Willmann, Jonas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t7dsdoe5v080jpqq15s8t7k2c9